Kahraman, S. Et Al. 2025. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy. Turkish Journal of Clinics and Laboratory , vol.16, no.2 , 255-262.

Kahraman, S., Hızal, M., Gümüşay, Ö., Başaran, G., Seyyar, M., Sahin, E., ... Çabuk, D.(2025). HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy. Turkish Journal of Clinics and Laboratory , vol.16, no.2, 255-262.

Kahraman, Seda Et Al. "HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy," Turkish Journal of Clinics and Laboratory , vol.16, no.2, 255-262, 2025

Kahraman, Seda Et Al. "HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy." Turkish Journal of Clinics and Laboratory , vol.16, no.2, pp.255-262, 2025

Kahraman, S. Et Al. (2025) . "HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy." Turkish Journal of Clinics and Laboratory , vol.16, no.2, pp.255-262.

@article{article, author={Seda Kahraman Et Al. }, title={HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy}, journal={Turkish Journal of Clinics and Laboratory}, year=2025, pages={255-262} }